0.72 USD
▲+0.03+0.78%
盘后 0.71 -0.39%
2026-08-03
市值
$40.19M
市盈率
—
EPS
-0.67
股息率
—
52 周区间
0.51 – 1.55
成交量
292.02K
Beta
1.58
目标价
7.50
52W 低 0.5152W 高 1.55
价格走势
公司简介
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma...